Gouty arthritis is a chronic disease, characterized by hyperuricemia, precipitating the deposition of infl ammatory monosodium urate (MSU) crystals in various tissues. Phagocytic uptake by monocytes and granulocytes of these crystals causes tissue infl ammation such as synovitis and often results in bone destruction. Under physiological conditions, the integrity of bone is maintained by the balanced activity of osteoclasts and osteoblasts, which are responsible for bone resorption and bone formation, respectively. Th e diff erentiation of monocytes into osteoclasts depends on the presence of the receptor activator of NF-κB ligand (RANKL) and is antagonized by osteoprotegerin. In chronic infl ammatory diseases, such as arthritis, a preponderance of RANKL leads to
bone loss by enhanced osteoclastogenesis. In the case of gout there has been evidence for an association between the occurrence of gouty tophi and bone destruction. Yet so far the mechanisms are still elusive.
In samples of gouty tissue Lee and colleagues observed osteolytic lesions close to the tophi [1] . Stromal tissue was infi ltrated with infl ammatory T cells, B cells, and mast cells, whereas the tophi themselves were surrounded by tartrate-resistant acid phosphatase-positive multinucleated osteoclasts. Th e occurrence of the latter may be explained by the presence of the pro-resorptive cytokines IL-1β, IL-6, and TNFα in the infi ltrated stromal tissue. Th ese cytokines reportedly enhance generation and activation of osteoclasts directly or indirectly via the induction of RANKL [2] . Analyzing CD3-expressing cells, the authors further claim a key role for T cells in bone destruction, since activated T cells in the tissue upregulate the expression of RANKL, considered the master regulator of osteoclastogenesis.
Twelve years ago Kong and colleagues fi rst reported that activated T cells promote osteoclastogenesis by the expression of RANKL [3] . Meanwhile several groups investigated the relationship between T cells and osteoclasts. In many osteolytic conditions (for example, rheuma toid arthritis or periodontal disease), RANKLexpressing T cells are located at the sites of increased bone resorption [4] . Lee and colleagues added gouty arthritis to this list [1] . Interestingly, we recently reported that, in contrast to eff ector T cells, regulatory T cells suppress osteo clasto genesis [5] . In this context, the exact subpopu lation(s) of T cells and the pathways responsible for the expression of RANKL within the infl amed gouty tissue are of major interest.
Lee and colleagues and others reported that MSU crystals induce the expression and the release of the proresorptive cytokines IL-1α, IL-1β, IL-6, and TNFα in monocytes in a dose-dependent manner [6, 7] . Th e upregulation and downregulation of RANKL and osteoprotegerin by MSU-stimulated T cells was observed 24 hours and, even stronger, 72 hours after co-incubation, respectively. Th e authors employed negatively selected highly enriched T cells (>95%) for their experiments, and
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In summary, bone destruction in gouty arthritis seems to be the result of an imbalance in bone remodeling. Th e overexpression of RANKL, presumably by infi ltrating T cells in a proinfl ammatory environment, promotes osteo clastogenesis. Concomitantly, the RANKL antagonist osteoprotegerin is downregulated. Tophus-associated mono cytes contribute IL-1β, IL-6, and TNFα, which act as additional promoters for osteoclast diff erentiation. Abbreviations IL, interleukin; MSU, monosodium urate; NF, nuclear factor; RANKL, receptor activator of NF-κB ligand; SFMC, synovial fl uid mononuclear cell; TNF, tumor necrosis factor.
